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ABSTRACT
After the progress made during the genomics era, bioinformatics was tasked with supporting the fl ow of information generated by 
nanobiotechnology efforts. This challenge requires adapting classical bioinformatic and computational chemistry tools to store, standardize, 
analyze, and visualize nanobiotechnological information. Thus, old and new bioinformatic and computational chemistry tools have been 
merged into a new sub-discipline: nanoinformatics. This review takes a second look at the development of this new and exciting area as seen 
from the perspective of the evolution of nanobiotechnology applied to the life sciences. The knowledge obtained at the nano-scale level 
implies answers to new questions and the development of new concepts in different fi elds. The rapid convergence of technologies around 
nanobiotechnologies has spun off collaborative networks and web platforms created for sharing and discussing the knowledge generated in 
nanobiotechnology. The implementation of new database schemes suitable for storage, processing and integrating physical, chemical, and 
biological properties of nanoparticles will be a key element in achieving the promises in this convergent fi eld. In this work, we will review 
some applications of nanobiotechnology to life sciences in generating new requirements for diverse scientifi c fi elds, such as bioinformatics 
and computational chemistry.
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1. INTRODUCTION
Richard Feynman introduced nanotechnology as a concept 
in 1979 during a conference at the California Institute of 
Technology. In that conference, Feynman gave an anticipatory 
talk, “There is Plenty of Room at the Bottom,” suggesting 
that individual atoms and molecules could be manipulated, 
allowing the controlled production of materials at the 
nanometer scale with promising technical, industrial, and 
biological applications (Drexler, 1992). This conference and 
its derived material would later be considered the theoretical 
starting point for the development of nanotechnology. Since 
then, nanotechnology has created a revolution, not only in the 
fi elds of physics, chemistry, materials science, engineering, 
environmental sensing, manufacturing, and quantum 
computing, but also with across-the-board applications in 
clinical research and biotechnology. Consequently, initiatives 
have created an international focus on new synthesis strategies, 
structures, phenomena, and properties associated with 
dimensional length scales residing between 1 and 100 nm 
(Tomalia, 2005).
Although many strategies have been applied to 
advance nanotechnology, a new approach, based on the 
organization, interpretation, and prediction of the structure 
and physical–chemical properties of nanoparticles and 
nanomaterials, is gaining momentum. The applications of 
computer technologies, information science, and molecular 
simulations have been gaining terrain as key methodologies 
to nanobiotechnology and nanoinformatics research; these 
methodologies are suitable to produce qualitative concepts, 
insights, and design suggestions. While bioinformatics is 
frequently related to the use of computational tools to analyze 
DNA and protein sequence data, nanoinformatics is applied 
in the context of characterizing particles and materials with 
application in nano- and biotechnology, by modeling and 
simulating them, in many instances at the atomic level, using 
computational chemistry strategies.
Introducing foreign bodies into the complex machinery 
of the human body is, however, a great challenge. Computer-
aided methods are the natural option to speed up the 
development of innovation in life sciences. However, new 
procedures for annotation and simulation of nanoparticle 
properties should be developed and analyzed to determine the 
limitations of computational methods applied in this fi eld.
The introduction of new information techniques to 
nanobiotechnology problems may accelerate the development 
of highly specific biomedical treatments, increase their 
effi ciency, and minimize their secondary effects, among other 
applications. In this contex the concept of nanomedicine 
emerges, which has advanced rapidly in the last fi ve years. A 
simple analysis of the number of web links related to the term 
“nanomedicine” shows exponential growth.
The first nanomaterials for biomedical sciences were 
designed in 1985, and since 2004, the term “nanomedicine” 
has been in widespread use. So far, the emergence of modern 
nano-biomedical sciences has been dominated by applications 
to biomedical problems, such as technological products from 
breakthrough synthetic methods in lipid (liposomes), polymer 
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(dendrimers), and colloid chemistry (metal colloids), and the 
discovery of entirely new chemical processes like fullerene and 
quantum-dot synthesis. All these new molecular systems have 
potential applications in diagnostics and therapy.
The lack of a common language as a mechanism for 
sharing knowledge is a huge impediment, especially in new 
disciplines. This emphasizes the need for governmental and 
other databases to organize and/or develop joint dictionaries 
and ontologies so that data can be collected more meaningfully. 
On the other hand, the nature and the amount of new data 
from nanotechnology efforts require GRID tools for their 
rapid analysis. Multi-scale datasets (from eM histopathology 
to molecular descriptors) are massive (15 Tb with current 
technologies) and analyses using combined data from multiple 
sources can only be achieved in a distributed environment, like 
GRID systems, which is the only realistic way to operate with 
this huge amount of information that in the near future can be 
combined with genomic information.
In what follows, we will analyze the state of the art in 
nanobiotechnology informatics by dividing the problem into 
four discrete areas, including social aspects (convergence of 
nanotechnology and medical sciences around nanoinformatic 
problems); new extension to classical bioinformatics methods; 
new modelling challenges, and the budding emergence of 
collaboratory environments, the later being a characteristic 
element of nearly every new nanoinformatics initiative.
2. CONVERGING TOWARD NANOBIOTECHNOLOGY
 AND NANOMEDICINE
This section will describe some of the tools and technologies 
that will accelerate the evolution of nanobiotechnology, such 
as new databases and storage systems adapted to process 
information generated in nanomedicine, critical for the design, 
modeling, simulation and visualization of nanosystems 
applied to the life sciences. As suggested before, the new data 
and knowledge obtained at the nano-scale level imply the 
development of new ontologies (nano-ontologies), to achieve 
a conceptual consensus of all information, terminology, and 
methodologies used in this fi eld.
Today, nanomedicine has branched out into hundreds 
of directions; each subdiscipline is developing the ability 
to manipulate structure and devices at the molecular scale, 
which can bring enormous and immediate benefi ts to medicine 
(ETP Nanomedicine, October 22, 2009; Freitas, 2005). These 
applications focus on treatment, monitoring, and diagnostics in 
new methods for drug administration and control of biological 
systems (ETP Nanomedicine, October 22, 2009; Farokhzad and 
Langer, 2006; Thierry, 2009).
Economic and other resources have been directed at 
developing new technologies in nanomedicine to reduce 
the mortality and morbidity rates, the prevalence of disease 
and the general social burden (ETP Nanomedicine, October 
22, 2009). The growing interest in nanomedicine and the 
exponential generation of data at the nano-scale level have 
enabled interdisciplinary groups to work together to create 
new nanoparticles with biomedical application. These data 
require an exhaustive analysis of their physical-chemical 
properties and an extensive structural characterization (ETP 
Nanomedicine, October 22, 2009; Farokhzad and Langer, 2006), 
which involves an intensive use of computational resources.
For these reasons, nanoinformatics emerged to satisfy 
the need to develop computational tools able to support the 
analysis of information generated each day in nanomedicine 
(García-Remesal et al., 2007; Gonzalez-Nilo Danilo and Cachau, 
2008; Iglesia et al., 2009). Nanoinformatics was supported 
in a fi rst stage by the U.S. National Science Foundation (de 
la Calle et al., 2009) and other international initiatives like 
the Action-Grid project. Another useful research initiative in 
nanomedicine is the BioInformatics Resource Inventory (BIRI). 
BIRI is an approach for automatically discovering and indexing 
available public bioinformatics resources, using information 
extracted from scientifi c literature. This tool is based on a 
domain-independent approach (De la Calle et al., 2008; García-
Remesal et al., 2007), that can be used to create inventories 
targeting different scientifi c fi elds. For now, this approach is 
currently being applied in the European Commission-funded 
Action Grid project.
Thus ,  nanomedic ine  i s  a  new f ie ld  ga ther ing 
the applications of nanotechnologies to healthcare (ETP 
Nanomedicine, October 22, 2009). This fi eld is led by several 
expert groups in Europe, such as the Nanomedicine Group 
of the Observatory for Micro-Nano Technologies (OMNT) 
(www.omnt.fr) in France, the European Technology Platform 
(ETP) the Nanomedicine platform (www.etp-nanomedicine.
eu), several cluster meetings organized by the European 
Commission on Personal Health Systems or on Micro-Nano-
Bio Convergence Systems, and some European networks such 
as Nano2life (http://www.nano2life.org/) and ACTION-Grid 
(http://www.action-grid.eu/).
With the need to extract, process, analyze, evaluate, 
and visualize the information generated in nanomedicine 
at the clinical level, new requirements have emerged for 
biomedical informatics (BMI). These new challenges will be 
resolved through the use of nanoinformatics and convergence 
technologies (NBIC) (Proyecto NBIC; Rodriguez, 2008), 
specifically information technology and communication 
technologies (ICTs) (Sommerfeld et al., 2009; Talbi and Zomaya, 
2007).
At the same time, a bioinformatics (databases/-omics) 
and computational chemistry approach (design/modeling/
simulation) can be used to evaluate nanosystems for 
nanomedicine in therapy and diagnostics. Initially, this area 
was unexploited due to the complex nature of biological and 
pharmacological systems, and also due to the expertise and 
interdisciplinary efforts required to formulate computational 
models for complex phenomena at the nano-scale level 
(Tentoni, 2003).
The application of nanosystems in personalized medicine, 
such as drug delivery systems and nanosystems for diagnostics 
and therapy, requires developing computational tools and 
methodologies for its modeling and simulation and the 
implementation of strategies to interpret the information 
generated after the interaction of specifi c organisms with these 
nanosystems.
Recent studies (Milanesi et al., 2009) have established a 
scheme where all the aforementioned components converge 
around the study of a complex biomedical system (see 
Figure 1). Several nanotechnological research lines emerge in 
health that can provide new ideas and concepts for solving 
pathological mechanisms and lead to novel therapeutic 
orientations.
45GONZÁLEZ-NILO ET AL. Biol Res 44, 2011, 43-51
3. NEW CHALLENGES FOR BIOINFORMATICS AND
 COMPUTATIONAL CHEMISTRY IN NANOBIOTECHNOLOGY
A computational approach is important in the early stages of 
project development at the nano-scale level. It can be used as 
a predictive technique in designing nano-transport systems 
for specifi c drugs or molecular devices (Tentoni, 2003; Thierry, 
2009). Large molecular systems are used today as vehicles or 
transportation platforms because they can be modifi ed with 
various chemical groups that confer solubility, affi nity, and 
selectivity for specifi c sites of a cell (Kang et al., 2009; Tentoni, 
2003; Thierry, 2009).
In recent years, computational molecular design has 
become an increasingly important fi eld in researching new 
nanomaterials (Rickman and LeSar, 2003); this results from 
increased calculational capacity and the consolidation of a 
number of methodologies of computational chemistry (Gao, 
2001).
Computational chemistry is a powerful tool to design, 
model, simulate, and visualize nanomaterials (Gao, 2001) and 
nanoparticles, such as dendrimers (Belting and Wittrup, 2009; 
Diekmann and Lindhorst, 2002; Newkome and Shreiner, 2007; 
Selim and Lee, 2009), metallic nanoparticles (Lee et al., 2009c; 
Murali Mohan et al., 2009; Prasad and Jha, 2010), nanocapsules 
(Fan and Hao, 2009), nanospheres (Lee et al., 2009a), and 
quantum dots (Kang et al., 2009). These nanoparticles are 
being used in nanomedicine as carriers, sensors, and systems 
for early diagnosis of diseases (Belting and Wittrup, 2009; ETP 
Nanomedicine, October 22, 2009; Kang et al., 2009).
Computer-assisted nanomolecule design has emerged 
from recent advances in computational chemistry and 
nanotechnology and is considered well suited for assisting the 
experimental community in the design of new nanostructures 
(Bewick et al., 2009). The major advantage of computational 
nano-design is that it provides a relatively inexpensive and 
rapid way to explore many structural designs, including the 
study of stability and prediction of properties (Shapiro et al., 
2008).
The application of modeling methods and nano-scale 
simulation to nano-design demands new methods or the 
adaptation of the techniques used in computational chemistry, 
such as classical molecular dynamics simulations (Fermeglia 
and Pricl, 2009; Gates et al., 2005), molecular mechanics 
(Shapiro et al., 2008) and quantum mechanics (Gates and 
Hinkley, 2004; Shapiro et al., 2008). Besides the use of these 
computational methods at the atomic level, it is necessary 
to implement new approaches in the use of quantitative 
structure–activity relationship (QSAR) studies in this fi eld 
(Shapiro et al., 2008).
Computational chemistry using molecular dynamics (MD) 
in nanostructures requires a good characterization of physical 
and chemical properties (Shapiro et al., 2008) to obtain accurate 
simulation results about the structural and dynamic properties 
of nanosystems at the atomic level (Gates et al., 2005). The 
Collaboratory for Structural Nanobiology (CNS) (http://
nanobiology.utalca.cl) is the fi rst initiative in the world that 
includes a database of nanoparticle structures. The fi rst stage 
of this initiative includes more than 120 models of dendrimers 
built using advanced molecular simulation techniques. CNS is 
an initiative of SAIC-NCI, USA, in collaboration with CBSM-
UTalca from Chile.
Computational chemistry using molecular mechanics 
(MM) can be used to determine the optimized structure of 
nanoparticles or nanomaterials (lowest energy conformation). 
Figure 1. Scheme for the convergence of different research lines from biomedicine to 
nanobiotechnology around the complex biomedical system.
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This is based on a model of molecules where spheres describe 
atoms and springs represent the bonds among them (Gates 
and Hinkley, 2004). The total energy of the molecule is 
calculated as the sum of energies implemented in a particular 
force field (energies of stretching, angles, torsion, VdW 
interactions, electrostatic interactions, and hydrogen bonds) 
(http://www.charmm.org/html/documentation/c34b1/
energy.html). Thus, modeling at the nano-scale requires force 
fi elds that are suffi ciently accurate for both the inorganic and 
organic components of the nanostructures. These features 
are extremely important for determining the 3D structural 
characteristics of nanostructures.
Computational chemistry also uses quantum mechanics 
(QM) such as semi-empirical, ab initio, and density functional 
theory (DFT) to predict the molecular structure at the 
electronic level of nanomaterials and to compute different 
molecular descriptors that depend on the electronic 
configuration of the system (Shapiro et al., 2008). These 
methods are limited not only by the number of degrees of 
freedom, but also by the time scale that requires this kind of 
calculations (http://www.charmm.org/html/documentation/
c34b1/energy.html; Shapiro et al., 2008). For this reason, 
the application of QM methods to nanoscale simulation for 
nanodesign demands new methods or an adaptation of the 
techniques traditionally used.
Several studies have been carried out using a cycle based 
on theoretical and experimental studies, with the aim of 
achieving a better understanding of systems at the nano-scale. 
For example, Haddish-Berhane et al. (Haddish-Berhane et al., 
2007) have studied a multiscale framework to integrate current 
computational approaches at different scales for drug delivery 
problems based on nanoparticles (Figure 2). It is expected that 
about 30% of pharmaceutical expenditure will be based on 
computer simulation, through an integrated effort between 
experimental and theoretical groups.
Theoretical models for the design of nanoparticles are 
diverse and use different approaches developed over the 
last 40 years in computational chemistry. For example, 
Deduzzi et al. et al., 2009b), using modeling techniques, have 
developed a theoretical study about size, shape, and surface 
of nanoparticles. Such features seem to play an important role 
when used as carriers and sensor systems in the intravascular 
journey.
Another example is the study by Pillay et al. (Sibeko et al., 
2009) that employed advanced computational tools to design 
a drug delivery system based on a biopolymeric membrane. 
Specifi cally, the group studied the infl uence of triethanolamine 
on the release properties of methotrexate from a composite 
biopolymeric membrane. Properties such as drug entrapment 
efficiency and the mechanisms of drug delivery have an 
important impact on the design of these kinds of systems. 
These properties require in-depth study and characterization 
at the molecular level. Thus, the design of new nano 
devices requires advanced computational tools to accelerate 
understanding of the mechanics of drug delivery.
Therefore, the need for accuracy and speed in the 
design of nanostructures requires the development of new 
computational chemistry methodologies or adaptation of 
existing ones to generate workfl ows and protocols to design 
suitable nanostructures.
4. MOLECULAR SIMULATIONS: KEY TECHNIQUES TO
 UNDERSTAND FUNDAMENTAL PHYSICOCHEMICAL
 PROPERTIES OF NANOPARTICLES
Simulation techniques have been widely used to model a 
variety of phenomena through a general approximation that 
treats the interacting particles as rigid spheres connected 
by springs. More recently, the development of force fi elds 
(Daggett, 2001; MacKerell, et al., 2000; Ponder and Case, 2003) 
suitable to perform biomolecular simulations permitted the 
study of diverse atomic level biological systems, ranging from 
a few thousand atoms (Artigas et al., 2008a; Barria et al., 2009; 
Gogonea et al., 2001; Gonzalez et al., 2008; Frisch 2004), up 
to the whole-organism, with the recently reported modelling 
of the complete TMV virus (Freddolino et al., 2006). Force 
fi elds used for biomolecular simulations (Case et al., 2005; 
MacKerell et al., 2000), such as CHARMM and AMBER, include 
both bonded and non-bonded interactions between all the 
represented atoms, plus expressions to model the effect of Van 
der Waals and Coulomb potentials, incorporating the system’s 
projected long-range effects induced by mass and charge 
(Daggett, 2001; MacKerell et al., 2000).
Despite the validity of the mathematical expressions that 
compose the available force fi elds, parameterization constants 
are included in all the bonded and non-bonded terms. These 
constants are fi ne-tuned, using either pure quantum mechanic 
calculations (ab initio) or empirically based approaches (Ponder 
and Case, 2003). When compared to wet-lab experiments, 
molecular simulation results have proven to be as accurate 
as typical experimental methods like microcalorimetry (Patra 
and Karttunen, 2004; Ponder and Case, 2003; Price and Brooks, 
2002). Thus, molecular simulations based on force fi elds have 
become a popular methodology to explore the behaviour of 
biomolecules at all the micro-, meso-, and nano-scales.
As noted before, molecular simulation techniques depend 
on the structure of the biomolecular system to be modelled. 
Consequently, there is much attention to developing databases 
to contain molecular structure data. Since the primordial 
research efforts dedicated to producing crystallographic 
structures of biomolecules in the 1970s, public databases, 
such as the Protein Data Bank (PDB; www.pdb.org, Rutgers 
University, the State University of New Jersey, and the 
University of California, San Diego, CA, USA), have grown to 
comprise more than 62.000 biomolecular 3D structures (nearly 
Figure 2. A framework for multi-scale modeling of drug delivery 
systems using information from drug and vehicle properties, 
disease pathology, and patient characteristics. Scheme adapted 
from Haddish-Berhane et al. (Haddish-Berhane et al., 2007).
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35,000 unique structures). However, the growth of unique folds 
at PDB and the results of joint international efforts, such as the 
Structural Genomics Project (Lundstrom, 2007; McGuffi n and 
Jones, 2002; Sali et al., 2007), demonstrate that we know only 
a portion of the different architectures and macromolecular 
arrangements in the human body. Moreover, the complexity 
of the intracellular environment complicates crystallization for 
many proteins. As a consequence, membrane-integral proteins 
such as channels and other transporters are usually under-
represented in databases like PDB.
Based on a  seminal  work f rom the  1980s  that 
demonstrated that the structure is more conserved than the 
sequence (Chothia and Lesk, 1986; Chothia et al., 1986), new 
methods to produce molecular models based on reference 
structures have been developed (Sali and Blundell, 1993; 
Sali et al., 1995; Sanchez and Sali, 2000). These methods, 
commonly known as comparative modelling techniques, are 
suitable under some restrictions, to produce models able to 
be used as sources for protein engineering (Colombres et 
al., 2008; Eyzaguirre et al., 2004) and computer-based drug 
design (Lagos et al., 2008; Lizama et al., 2009; Vasquez et al., 
2007), to explore structure–function relationships (Artigas et 
al., 2008b; Barria et al., 2009; Carvajal et al., 2003; Ehrenfeld 
et al., 2008; Stange et al., 2008; Strobel et al., 2005; Tischler et 
al., 2005), and signal-transducing mechanisms (Gonzalez et 
al., 2008; Inestrosa et al., 2005; Strobel et al., 2004), among a 
variety of applications.
Extensive efforts have been made at the experimental level 
to characterize the fundamental physicochemical properties 
of nanoparticles with potential applications in biomedical 
sciences. However, all these efforts have faced the limits 
of current experimental techniques, because the nanoscale 
has proven to be too small for light microscopy, while too 
polydisperse for x-ray crystallography, too heterogeneous 
for NMR, and too “wet” for electron microscopy (Lu et al., 
2006). Under these circumstances, molecular modelling and 
simulation techniques have arisen as key methodologies to 
nanobiotechnology research, suitable to produce qualitative 
concepts, insights, and design suggestions. Thus, quantum 
mechanics, molecular modelling and molecular simulation 
techniques provide representations of nanosystems at 
the atomic level with electronic resolution, offering a 
suitable framework for the characterization of diverse 
physical-chemical properties of nanosystems. Advancing 
in these efforts, the reports of several molecular dynamics 
(MD) simulations of nanoparticles and other nanosystems 
demonstrated the suitability of these computer-based 
techniques to explore and understand basic properties of 
nanoparticles and nanomaterials (Cieplak and Thompson, 
2008; Khurana et al., 2006; Martin et al., 2008; Zimmerli and 
Koumoutsakos, 2008). Moreover, these tools provide a unique 
source of information not only to model basic nanoparticle 
properties, but also to gain insight into interactions with 
biological systems. The application of computer-intensive 
methods like hybrid quantum mechanics and molecular 
dynamic (QM/MM) simulations, enriched with proper 
algorithms to effi ciently sample the vast conformational space, 
will permit characterizing a wide variety of nanoparticle 
properties, obtaining insights into the biological phenomena 
that command nanoparticle recognition by physiological 
systems (Arayne et al., 2007; Archakov and Ivanov, 2007; 
Bianco, 2004).
5. DEVELOPMENT OF COLLABORATIVE NETWORK
 PLATFORMS FOR NANOBIOTECHNOLOGY
5-a. Design web portals
To facilitate data-sharing (recent literature, tutorials, papers, 
links, and access points to nanomedical databases; jobs, and 
news, updated daily) in the research community to expedite 
and validate the use of nanoparticles, nanomaterials, and 
nanosystems in nanomedicine (ETP Nanomedicine, October 22, 
2009; Gordon and Sagman, 2003). Nanowerk Nanotechology 
Portal (http://www.nanowerk.com), NanoLink (http://
www.nano-link.net), and CaNanoLab (http://cananolab.
abcc.ncifcrf.gov) are clear examples of portals dedicated to 
promoting the information generated in nanomedicine and 
nanotechnology. The fi rst is a portal with a great variety of 
links to and directories about nano research, daily news, and 
nanotechnology feature articles, reports, an events calendar, 
and a nanomaterial database focused on nanomedicine 
(NanoLink is a web portal). The second portal links to sites 
that focus on life quality through technological innovation 
(LINK=Life quality through Innovation by a Network of 
Knowledge). NanoLINK will be a consolidated network 
of networks focused on nanotechnology (nanoLINKnet) 
(Nanowerk Nanotechnology Portal). CaNanoLab is also a web 
portal focused on dissemination of nanobiological information 
across the scientifi c community (The Cancer Nanotechnology 
Laboratory (caNanoLab) Portal).
5-b. Implementation and maintenance of forums
Forums provide a platform of interactive communication 
to discuss the new possibilities offered by nanotechnology 
in medicine and thus promote technology and information 
transfer among different areas of science, health, the 
pharmaceutical industry, and education, among others, 
sustained through nanoinformatics. Such forums include the 
Nanoforum (http://www.nanoforum.org/), NanoNewsBoard 
Forum (http://www.amtexpo.com/nano/), and the Institute 
of Nanotechnology Forum (http://www.nano.org.uk/forum/
index.php). The Nanoforum was developed by the European 
Commission through FP5 to disseminate the advances of 
different areas of nanotechnology, including, of course, the 
development of nanomedicine, its current outlook, and its 
projections based on the successful discussion of nano-scale 
research (Funding and Support for International Nanotechnology 
Collaborations Nanoforum  report, December 2005). The 
second forum, NanoNewsBoard, is a nanotechnology forum 
sponsored by Access Multimedia Technology, Inc. (USA) 
(NanoNewsBoard); and the third forum was implemented 
by the Institute of Nanotechnology (IoN-UK) (Institute of 
Nanotechnology Forum). Both forums contain nanotechnology 
news, including nanomedicine (ETP Nanomedicine, October 
22, 2009). These forums update users on the latest advances in 
applying nanotechnology to medicine.
5-c. Development of thematic networks and collaboration
Nanotechnology networks and collaborations are being 
developed to facilitate interaction among professionals 
(collaborations among groups with different expertise and 
resources [technical, scientifi c, social and political]) working at 
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the intersection between biomedical information and nanoscale 
health information (Funding and Support for International 
Nanotechnology Collaborations Nanoforum report, December 2005; 
Gonzalez-Ibanez et al., 2009). These networks are needed so 
experts can share (Open access and dissemination of data and 
tools, i.e., Open Source), promote, and improve standards of 
biomedical information generated at the nano-scale (Nanohub 
Forum; National Institutes of Health [NIH], 2006) and allow 
users anywhere in the world easy access to information. 
Examples of current thematic networks and collaborations are: 
The Collaboratory for Structural Nanobiology (CSN) (http://
csn.ncifcrf.gov/csn), the nanoHUB (http://nanohub.org/), 
and NanoMedNet (http://www.nano.org.uk/nanomednet/). 
The first is a nanobioinformatic web service dedicated to 
collecting, curating, and correlating structural, physical-
chemistry, biological, and biomedical data (The Collaboratory 
for Structural Nanobiology). The second is a web platform 
for research, education, and collaboration in nanotechnology 
(Nanohub Forum). The third, NanoMedNet, is a collaboration 
web platform that promotes information about various aspects 
of the emerging fi eld of nanomedicine and develops services, 
tools, and education and training for medical professionals 
related to nanomedicine (NanoMedNet).
5-d. Creation of storage systems and data exchange
The major increase of data and information generated 
through measurement or calculation of physical and 
chemical properties of nanostructures and nanomaterials 
(The cancer Nanotechnology Laboratory [caNanoLab] 
Portal), mathematical models from clinical nanomedicine 
(Bewick et al., 2009), taxonomy of nanomedical application 
(Gordon and Sagman, 2003), nano-ontologies (The cancer 
Biomedical Informatics Grid [caBIG]), high-throughput 
experimentation/discovery (Tentoni, 2003), tools for visual 
analysis of nanoimages (Mauger et al., 2007) and data-mining 
of biomedical data (Zweigenbaum et al., 2007), require the 
creation and implementation of systems and tools for sharing 
and storing this information.
The creation of databases or repositories (Database of 
Nanoparticles; Mauger et al., 2007; Sommerfeld et al., 2009) to 
allow the exchange of information about the 3-D structural and 
data of the physical and chemicals properties of nanoparticles 
with biomedical applications, such as dendrimers, nanotubes 
and metal particles, and quantum dots, among others, is 
critical for the multidisciplinary development of nanomedicine.
Biomedical data are being generated at different levels. 
Specifically, the atomic level (nanomedicine) has seen an 
explosive increase (ETP Nanomedicine, October 22, 2009). This 
large fl ow of information requires secure and easily available 
storage systems. The current information storage systems, 
called data warehouses, can be expanded to accommodate 
the information generated in nanomedicine. Thus, the data 
warehouses (Sommerfeld et al., 2009; Staggers et al., 2008; Talbi 
and Zomaya, 2007) can be optimized through nanoinformatic 
tools and the technologies of information and communication 
(TICs) as storage systems for nano-scale systems useful in 
medicine.
Several projects in this area have been developed. This is 
the case with the structural database CSN (http://nanobiology.
utalca.cl), The CaNanoDB (https://gforge.nci.nih.gov/
projects/canano/) and The ICON EHS Database (http://icon.
rice.edu/research.cfm). The fi rst is a structural database of 
various nanoparticles with possible nanomedical applications. 
This site offers downloadable nanopdb fi les, related research 
data, and resources for visualization of different nanoparticles, 
such as dendrimers, nanotubes and metallic particles (CSN). 
The second, caNano Database (CaNanoLab), includes all 
available technologies and a toolbox for modeling targeted 
drug delivery and diagnostics using nanoparticles as 
transport platforms (The cancer Nanotechnology Laboratory 
[caNanoLab] Portal). The third project is a database that 
contains summaries (abstracts) and citations for research 
papers related to the health and safety implications of 
nanoscale materials (The ICON EHS Database).
CONCLUSION
Bioinformatics and molecular simulations have evolved 
around biotechnology related problems helping the 
researcher explore complex problems from genome analysis 
to protein structure. Now, the accelerated convergence of 
biotechnology and nanotechnology poses new challenges to 
the information and modeling fields. The newer scientific 
fi elds of nanobiotechnology and nanomedicine present a great 
opportunity for the scientifi c community to merge many of 
the concepts and tools developed during the past few decades 
in computational chemistry and computational biology. The 
tools of these fi elds, such as databases, storage, ontologies, and 
annotation (bioinformatics), should be merged with design, 
modeling, simulation, and visualization (computational 
chemistry) of nanosystems, to generate a new sub-discipline: 
nanoinformatics.
The applications of nanotechnology in medicine and 
biotechnology require advanced approaches to manipulate 
nanoparticles data at the molecular level (nano-scale); these 
approaches are complex and are frequently handled through 
the implementation of collaborative networks and the creation 
of web platforms for sharing and discussing the knowledge 
generated.
As indicated in the previous sections, the impact of 
molecular modelling and simulations in nanobiotechnology 
has been steadily increasing during the last decade. Molecular 
modelling and simulations offer a unique way to explore 
interactions at different scales that range from thousands of 
atoms, to even millions of them. Through these simulations, 
fundamental physicochemical properties of nanoparticle and 
other nanoscale systems can be studied. The ever-increasing 
capacity of modern computer platforms, together with a 
systematic price reduction, will allow the embedding of 
molecular simulations in different nanotechnology sub-fi elds. 
The identifi cation of the intermediate complexity modules that 
defi ne and control the properties of complex nanodevices will 
be a main objective of many of these computer simulations 
given the importance of modular approaches in the rational 
design of engineered nanomaterials.
The implementation of new database schemes suitable to 
store and to process data generated in nanobiotechnology –
connecting physical, chemical, and biological properties of the 
nanoparticle– will be a key element in deriving the knowledge 
needed to develop this quality of information.
Thus we can envision the emergence of nanoinformatics as 
a new discipline comprising the vast set of computer-related 
tools to model, store, and analyze nanotechnology highly 
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diverse data with an increasing role of atomic level simulation 
tools in the nanodesign cycle.
The implementation of these new techniques may 
accelerate the development of highly specific biomedical 
treatments through design, increasing nanobiomaterials 
efficacy, specificity and bioavailability, while minimizing 
secondary effects, opening the door to a new era of 
personalized medicine with materials designed from the bottom 
up. (Drexler, 1992, citing Feynman, 1959).
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